FDA Approves Shingrix for Shingles
The FDA approved GlaxoSmithKline’s Shingrix vaccine for treatment of shingles in adults 50 and over.
An FDA advisory committee endorsed Shingrix in September.
Shingrix is a non-live, recombinant subunit vaccine for shingles and its complications, such as postherpetic neuralgia.
Merck’s Zostavax is the only other FDA-approved shingles vaccine.